Even though, to date, recombinant forms of TRAIL, and agonistic antibodies against TRAIL-R1 and TRAIL-R2 have failed to provide clinical benefit in cancer patients, novel cross-linking agonistic TRAIL-R antibodies are currently under evaluation (76, 77) and different approaches have been undertaken to re-sensitize transformed cells to TRAIL (31, 62, 78). Here, TNFSF10 is linked to cancer.